APOL1 and chronic kidney disease: Early studies reported no correlation between circulating APOL1 levels and its G1/G2 mutations (Bruggeman et al., 2014; Weckerle et al., 2016; Andrews et al., 2022), which confer resistance to T. b. rhodesiense and significantly increase CKD risk (Friedman and Pollak, 2020).